NCT06333769View on ClinicalTrials.gov

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 12, 2024

Primary Completion Date

August 10, 2025

Study Completion Date

August 14, 2025

Conditions
Mid-low Rectal Cancer
Interventions
RADIATION

Short-course Radiotherapy

Rectal lesion + metastatic lymph nodes, GTV 30Gy/5Fx. Pelvic lymphatic drainage area, CTV 22.5Gy/5Fx.

DRUG

Tislelizumab

Tislelizumab：200mg，d1，q3w，2 cycles.

DRUG

Capecitabine

Capecitabine：1000mg/m2，d1-14，bid, q3w, 2 cycles.

DRUG

Oxaliplatin

Oxaliplatin：130mg/m2, d1, q3w, 2 cycles

Trial Locations (3)

350014

Fujian Cancer Hospital, Fuzhou

362200

Jinjiang Municipal Hospital, Quanzhou

364000

The Second Hospital of Longyan, Longyan

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT06333769 - Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter